The associations representing the European and British life science industry (AESGP, ABPI, BGMA, BIA, EBE, EFPIA, EUCOPE, EuropaBio, Medicines for Europe, PAGB, Vaccines Europe) have today launched a joint policy document on the potential impact of the United Kingdom’s exit from the European Union

14 December 2017

Today, organisations representing the life science industry in the EU […]

European Commission launches: “What I need to know about Biosimilar Medicines – Information for patients”, in 23 EU languages

29 November 2017

The European Commission launched today additional translations of the Q&A […]

Europe’s life science industry urges the UK and EU27 to safeguard patients’ access to medicines with a clear transition period and a future cooperation agreement after Brexit

28 November 2017

The associations representing the European and British life science industry […]

Medicines for Europe calls for greater cooperation on value added medicines to improve patient-centric innovation

22 November 2017

The 1st Value Added Medicines conference organised by the Value […]

Medicines for Europe welcomes decision on EMA relocation to Amsterdam

21 November 2017

Medicines for Europe is very glad to see the Council […]

Commission sponsored study shows Supplementary Protection Certificate (SPC) Manufacturing Waiver will create Jobs, strengthen the pharmaceutical sector and reduce medicine costs

18 October 2017

On Thursday 12 October, the Directorate-general for Internal Market, Industry, […]

Medicines for Europe announces new President, launches Access to Medicines campaign

10 October 2017

The newly elected President of Medicines for Europe – Marc-Alexander Mahl – […]

Medicines for Europe to join the ISPOR Issue Panel on value added medicines

5 October 2017

Value added medicines represent a major opportunity to improve patients’ […]

Addressing medicine shortages in Europe: Competition is crucial for patient access

29 September 2017

Generic medicines have proven to be pivotal in increasing patient […]

2017 Biosimilar Medicines Policy Overview: better access is crucial; tailored solutions essential for EU governments

12 September 2017

Biosimilar medicines are transforming treatment by enabling better access to […]

Newsroom

News about

By type

Twitter

Videos

Photos

The associations representing the European and British life science industry (AESGP, ABPI, BGMA, BIA, EBE, EFPIA, EUCOPE, EuropaBio, Medicines for Europe, PAGB, Vaccines Europe) have today launched a joint policy document on the potential impact of the United Kingdom’s exit from the European Union

14 December 2017

European Commission launches: “What I need to know about Biosimilar Medicines – Information for patients”, in 23 EU languages

29 November 2017

Europe’s life science industry urges the UK and EU27 to safeguard patients’ access to medicines with a clear transition period and a future cooperation agreement after Brexit

28 November 2017

Medicines for Europe calls for greater cooperation on value added medicines to improve patient-centric innovation

22 November 2017

Medicines for Europe welcomes decision on EMA relocation to Amsterdam

21 November 2017

Commission sponsored study shows Supplementary Protection Certificate (SPC) Manufacturing Waiver will create Jobs, strengthen the pharmaceutical sector and reduce medicine costs

18 October 2017

Medicines for Europe announces new President, launches Access to Medicines campaign

10 October 2017

Medicines for Europe to join the ISPOR Issue Panel on value added medicines

5 October 2017

Addressing medicine shortages in Europe: Competition is crucial for patient access

29 September 2017

2017 Biosimilar Medicines Policy Overview: better access is crucial; tailored solutions essential for EU governments

12 September 2017

Subscribe to our newsletter

Share on Mastodon